MedTrace Logo

Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer

NCT00613626 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2020-02-11

Study results available
· View outcomes & findings →

Summary

At this point in the treatment of extensive stage SCLC, we have reached a plateau in survival with conventional chemotherapy and newer regimens are greatly needed. It has been noted that patients with increased VEGF levels have a poorer prognosis. Anti-angiogenic agents hold significant promise in the treatment of patients with extensive stage SCLC. ZD6474, a new inhibitor of the VEGFR-2, has shown favorable action in NSCLC.

Conditions

Interventions

DRUG

Cisplatin

Cisplatin 60 mg/m2 IV day 1 every 21 days for a total of 4 cycles

DRUG

Etoposide

Etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles

DRUG

Placebo

Matched placebo oral daily

DRUG

ZD6474

ZD6474 100mg oral daily to be continued for the duration of the study.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Hoosier Cancer Research Network

    lead OTHER

Principal Investigators

  • Nasser Hanna, M.D. · Hoosier Oncology Group, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00613626 on ClinicalTrials.gov